Trial Profile

A Phase II Platform Trial of Perioperative Therapies in Locally Advanced Unresectable Gastric Cancer (Neo-VIKTORY)

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 06 Jul 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Capecitabine (Primary) ; Capecitabine (Primary) ; Durvalumab (Primary) ; Oxaliplatin (Primary) ; Rilvegostomig (Primary) ; Sonesitatug vedotin (Primary) ; Trastuzumab-deruxtecan (Primary)
Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
Focus Adverse reactions
Acronyms Neo-VIKTORY

Most Recent Events

01 Jul 2026 Arms increased from 2 to 4 with addition of Capecitabine, Durvalumab, sonesitatug Vedotin, and Oxaliplatin. Design changed from randomized to non-randomized.
01 Jul 2026 Planned number of patients changed from 50 to 100.
15 Dec 2025 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com